{
  "@context": "https://frontierpicks.com/schemas/dossier.v1.json",
  "ticker": "DVA",
  "name": "DaVita Inc.",
  "url": "https://frontierpicks.com/dossiers/DVA/",
  "json_url": "https://frontierpicks.com/dossiers/DVA.json",
  "status": "DORMANT",
  "current_conviction": "LOW",
  "graded_conviction": null,
  "archetype": {
    "code": "a4",
    "n": 4
  },
  "current_thesis": "The $175 weekly-close level from the prior note broke: DVA closed 2026-08-21 at $173.82, 27.9% under the $240.96 high, RSI(14) 10.9, with no company news or filing since the 2026-08-04 Q2 print. The census-recovery re-rate is dead; sell-side marks near $215 still sit well above spot, and nothing is scheduled inside 30 days to resolve the H2 revenue-per-treatment question.",
  "invalidation_trigger": "A weekly close below $165 takes DVA under the lowest published 12-month target in the 2026-08-20 aggregated range and confirms a de-rating on the H2 revenue-per-treatment guide rather than a print-reaction overshoot; secondary: FY26 adjusted EPS revised below the $14.10 low end at the Q3 print (~2026-10-28, est.).",
  "catalyst_date": null,
  "outcome": "OPEN",
  "outcome_date": null,
  "invalidation_fired": null,
  "themes": [
    "managed-care-health-services"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Berkshire Hathaway is the largest holder and a recurring seller; a standstill-linked repurchase agreement keeps its stake at or below 45%, tying buyback size to that cap.",
    "Beta ~0.84-0.91. A defensive, low-volatility dialysis operator that re-rates on prints and estimate revisions rather than on tape velocity.",
    "CMS ESRD PPS rate-setting and recurring DaVita-versus-insurer litigation are permanent background variables for this name.",
    "Net leverage was 3.37x at the 2026-08-04 Q2 report; buybacks and deleveraging compete for the same free cash flow.",
    "DaVita had not announced a Q3 2026 conference-call date as of 2026-08-21; recent years put the Q3 print in late October."
  ],
  "body_markdown": "## Current Thesis\nThe $175 weekly-close condition flagged in the 2026-08-08 note came and went. DVA closed Friday **2026-08-21 at $173.82**, **27.9% below the $240.96 52-week high**, with **RSI(14) at 10.9** — down from 19.7 two weeks earlier. Nothing company-specific was announced or filed between the **2026-08-04** Q2 print and that close: the company's public news and filing feed shows the 08-04 results release as the most recent item. So the additional slide is the market continuing to mark down the H2 revenue-per-treatment guide, with no new information to argue about. The census-recovery re-rate that carried this name off the **$103.87** 52-week low is finished as a narrative leg. What is left is a cash-generative dialysis operator trading below the lowest end of some published target ranges, with the sell-side mean still sitting far above spot — a configuration where the marks, not the price, are the stale number. The shares are down **12.4%** over three months.\n\n## Bull Case\n- management moved FY treatment growth to the **top end of the 25–50bps range** (2026-08-04 release and call). Census **~298,500 patients** across **3,266** outpatient centers.\n- **Share count is shrinking into the drawdown.** **2.2M shares repurchased for $348M** in Q2, **$751M year to date**, against an FY free-cash-flow guide of **$1.0–1.25B** (2026-08-04). At the 2026-08-21 close of $173.82, the same dollar retires materially more stock than at the pre-print level near **$228** (Simply Wall St, 2026-08-05).\n- **Both lines beat.** Adjusted EPS **$4.02** versus **$3.88** consensus; revenue **$3.554B** versus **$3.496B** (2026-08-04).\n- **Published targets sit above spot.** TD Cowen upgraded to **Buy** with a **$220** target (2026-08-05); Barclays raised to **$224** the same day; Truist held at **$215**, cut from **$250**. Aggregations as of **2026-08-20** show a mean near **$214.83** across 6 analysts and **$218.43** across 7, range **$165–$270**.\n- **No visible new insider supply.** As a >10% holder Berkshire discloses DVA sales on Form 4 within days; the public filing feed showed no DVA Form 4 between **2026-08-04** and **2026-08-21**. Absence of a filing is weaker evidence than a filing, but it is the observable.\n\n## Bear Case\n- **The 2026-08-05 session was a break, not a wobble.** Prior close near **$228** to roughly **$189** — a **17% single-day decline** (Simply Wall St, 2026-08-05) — on an earnings *beat*. The market rejected an FY26 adjusted EPS range **affirmed** at **$14.10–$15.20** (midpoint **$14.65**) against **$14.82** consensus.\n- **Revenue per treatment went backwards.** **$415.87** in Q2 versus **$417.59** in Q1; FY RPT growth guided **1–2%**, which management said implies slightly negative year-over-year RPT in H2 on declining ACA-driven commercial mix and lower phosphate-binder revenue (2026-08-04 call).\n- **Costs are running ahead of the guide.** Simply Wall St's 2026-08-05 read of the Q2 disclosure puts year-to-date patient care cost growth above **3%** against an FY expectation of **1.25–2.25%**, with quarterly interest expense of **$152M** and net leverage at **3.37x**. H2 has to decelerate on costs for the operating-income guide of **$2,150–2,250M** to hold.\n- **Every shelf named in prior coverage is gone.** The **$203** June breakout level went in the print week; **$175** went on the 2026-08-21 weekly close. RSI(14) at **10.9** describes near-continuous distribution over three weeks.\n- **One published target is already under spot.** The **$165** low in the 2026-08-20 aggregated range sits below the $173.82 close, and two of the three post-print analyst actions on 2026-08-05/07 were target cuts.\n\n## Setup & Price Structure\nThe 2026-08-21 close of **$173.82** sits inside a 52-week range of **$103.87–$240.96**. The overhead structure is the **2026-08-05** gap from roughly **$228** to **$189**; nothing has traded back into it in the eleven sessions since. RSI(14) of **10.9** is an extreme reading — worth naming as a description of how one-sided the tape has been, not as a signal that a low is in. No base has formed: the last identifiable horizontal shelf below spot is unbuilt, and the first serious reference beneath is the **$165** low target.\n\nThe narrative is **dead**. The dating is specific — **2026-08-05** (17% single-day break on a beat), **2026-08-07** (targets marked down to $215/$220 from levels that had been *below* the pre-print price), and **2026-08-21** (weekly close through the $175 floor named in the prior note). Narrative failed and structure broken are both satisfied on the tape.\n\nCrowding and positioning observables, stated as observables: there is **no imminent earnings date** — DaVita had not scheduled a Q3 call as of 2026-08-21, and recent years put Q3 in late October. Price is **below**, not extended above, any rising moving average, so the usual overbought-distance measure does not apply here. The company is **retiring** stock rather than issuing it (**$348M** in Q2). Insider supply from the largest holder is disclosed near real time and none appeared in the drawdown window. Retail-facing coverage clusters around value screens (\"strong ROE\", \"21% potential upside\", directorstalkinterviews.com pieces dated August 2026) rather than momentum, which is what late-drawdown coverage typically looks like.\n\n## Catalyst Calendar (next 30 days)\n- **2026-08-22 to 2026-09-21 — nothing scheduled.** No company event, no print, no rule-making deadline falls inside the window. The **2026-08-14** Q2 13F deadline has passed and its read-through was always limited, since Berkshire discloses DVA sales on Form 4 well ahead of any 13F.\n- **~2026-10-07 to 2026-10-14 (est.)** — historical timing for the company to announce its Q3 conference-call date. Outside the window.\n- **~2026-10-28 (est.)** — Q3 2026 print. Outside the window; it is the first hard datapoint on the H2 RPT question.\n- **~2026-10-31 (est.)** — CMS ESRD PPS CY2027 final rule. Outside the window.\n- **2026-11-01** — ACA marketplace open enrollment for plan year 2027 begins. Outside the window, but it is the direct input into the commercial-mix variable management named on 2026-08-04.\n\n## What Would Change Our Mind\nThe structural argument that has already failed is the $175 floor: it broke on the 2026-08-21 weekly close, which is the outcome the 2026-08-08 note said would reframe this as a de-rating rather than a print-reaction overshoot. That reframe is now the working read, and it breaks in either direction on observable conditions.\n\nDownside confirmation: **a weekly close below $165** would take price under the lowest published 12-month target in the 2026-08-20 aggregated range and put the drawdown deeper than the 2026-08-05 gap low without any new information to explain it. A secondary condition is fundamental: FY26 adjusted EPS revised **below the $14.10 low end** at the Q3 print (~2026-10-28, est.), or Q3 revenue per treatment printing under the Q2 **$415.87**.\n\nUpside repair: a **weekly close back above $189** would put price inside the 2026-08-05 gap and argue the mark-down is complete. Confirming fundamentals would be Q3 RPT flat-to-up sequentially, adjusted operating income tracking above the pace required for the **$2,150M** low end, and a raise off the **$14.65** midpoint. A resumption of Berkshire Form 4 sales below the ~**28.7M** shares disclosed 2026-08-04 would work against that repair by adding supply into it.\n\n## Correlation Notes\n- **Beta ~0.84–0.91.** A defensive, low-volatility operator whose re-ratings come from prints and estimate revisions rather than tape velocity; the 17% single-day move on 2026-08-05 is far outside that behaviour and was event-driven.\n- **Commercial-mix exposure links DVA to ACA marketplace enrollment**, a variable shared with managed-care insurers. Management named declining ACA enrollment as a driver of the Q2 sequential RPT decline on 2026-08-04, so 2027 open-enrollment data (from 2026-11-01) is a shared read-through.\n- **Fresenius Medical Care is the only comparable listed dialysis operator.** Prior coverage flagged the absence of a sympathetic peer bid through this drawdown; that has not changed on any dated evidence through 2026-08-21.\n- **The Berkshire repurchase agreement mechanically ties buyback size to the 45% stake cap.** The **2026-05-01** open-market sale of **1,220,376 shares at an average $149.84** lowered the stake to **44.9%** under that agreement, so the buyback and the largest holder's supply are linked rather than independent.\n- **CMS ESRD PPS rate-setting is a policy factor common to every US dialysis provider**, which is why the CY2027 final rule (~2026-10-31, est.) is a sector event rather than a company-specific one.",
  "first_seen": "2026-05-19",
  "last_analyzed": "2026-08-22T08:17:30+00:00",
  "last_synthesized": "2026-08-22",
  "last_update_source": "watchlist_research",
  "license": "Content © FrontierPicks. Cite the canonical URL."
}